Skip to main content
Journal of Biomedicine and Biotechnology logoLink to Journal of Biomedicine and Biotechnology
. 2005;2005(2):160–171. doi: 10.1155/JBB.2005.160

Multiclass Cancer Classification by Using Fuzzy Support Vector Machine and Binary Decision Tree With Gene Selection

Yong Mao 1, Xiaobo Zhou 2, Daoying Pi 1, Youxian Sun 1, Stephen T C Wong 2,*
PMCID: PMC1184049  PMID: 16046822

Abstract

We investigate the problems of multiclass cancer classification with gene selection from gene expression data. Two different constructed multiclass classifiers with gene selection are proposed, which are fuzzy support vector machine (FSVM) with gene selection and binary classification tree based on SVM with gene selection. Using F test and recursive feature elimination based on SVM as gene selection methods, binary classification tree based on SVM with F test, binary classification tree based on SVM with recursive feature elimination based on SVM, and FSVM with recursive feature elimination based on SVM are tested in our experiments. To accelerate computation, preselecting the strongest genes is also used. The proposed techniques are applied to analyze breast cancer data, small round blue-cell tumors, and acute leukemia data. Compared to existing multiclass cancer classifiers and binary classification tree based on SVM with F test or binary classification tree based on SVM with recursive feature elimination based on SVM mentioned in this paper, FSVM based on recursive feature elimination based on SVM can find most important genes that affect certain types of cancer with high recognition accuracy.

INTRODUCTION

By comparing gene expressions in normal and diseased cells, microarrays are used to identify diseased genes and targets for therapeutic drugs. However, the huge amount of data provided by cDNA microarray measurements must be explored in order to answer fundamental questions about gene functions and their interdependence [1], and hopefully to provide answers to questions like what is the type of the disease affecting the cells or which genes have strong influence on this disease. Questions like this lead to the study of gene classification problems.

Many factors may affect the results of the analysis. One of them is the huge number of genes included in the original dataset. Key issues that need to be addressed under such circumstances are the efficient selection of good predictive gene groups from datasets that are inherently noisy, and the development of new methodologies that can enhance the successful classification of these complex datasets.

For multiclass cancer classification and discovery, the performance of different discrimination methods including nearest-neighbor classifiers, linear discriminant analysis, classification trees, and bagging and boosting learning methods are compared in [2]. Moreover, this problem has been studied by using partial least squares [3], Bayesian probit regression [4], and iterative classification trees [5]. But multiclass cancer classification, combined with gene selection, has not been investigated intensively. In the process of multiclass classification with gene selection, where there is an operation of classification, there is an operation of gene selection, which is the focus in this paper.

In the past decade, a number of variable (or gene) selection methods used in two-class classification have been proposed, notably, the support vector machine (SVM) method [6], perceptron method [7], mutual-information-based selection method [8], Bayesian variable selection [2, 9, 10, 11, 12], minimum description length principle for model selection [13], voting technique [14], and so on. In [6], gene selection using recursive feature elimination based on SVM (SVM-RFE) is proposed. When used in two-class circumstances, it is demonstrated experimentally that the genes selected by these techniques yield better classification performance and are biologically relevant to cancer than the other methods mentioned in [6], such as feature ranking with correlation coefficients or sensitivity analysis. But its application in multiclass gene selection has not been seen for its expensive calculation burden. Thus, gene preselection is adopted to get over this shortcoming; SVM-RFE is a key gene selection method used in our study.

As a two-class classification method, SVMs' remarkable robust performance with respect to sparse and noisy data makes them first choice in a number of applications. Its application in cancer diagnosis using gene profiles is referred to in [15, 16]. In the recent years, the binary SVM has been used as a component in many multiclass classification algorithms, such as binary classification tree and fuzzy SVM (FSVM). Certainly, these multiclass classification methods all have excellent performance, which benefit from their root in binary SVM and their own constructions. Accordingly, we propose two different constructed multiclass classifiers with gene selection: one is to use binary classification tree based on SVM (BCT-SVM) with gene selection while the other is FSVM with gene selection. In this paper, F test and SVM-RFE are used as our gene selection methods. Three groups of experiments are done, respectively, by using FSVM with SVM-RFE, BCT-SVM with SVM-RFE, and BCT-SVM with F test. Compared to the methods in [2, 3, 5], our proposed methods can find out which genes are the most important genes to affect certain types of cancer. In these experiments, with most of the strongest genes selected, the prediction error rate of our algorithms is extremely low, and FSVM with SVM-RFE shows the best performance of all.

The paper is organized as follows. Problem statement is given in “problem statement.” BCT-SVM with gene selection is outlined in “binary classification tree based on SVM with gene” selection. FSVM with gene selection is described in “FSVM with gene selection.” Experimental results on breast cancer data, small round blue-cell tumors data, and acute leukemia data are reported in “experimental results.” Analysis and discussion are presented in “analysis and discussion.” “Conclusion” concludes the paper.

PROBLEM STATEMENT

Assume there are K classes of cancers. Let w = [w1, . . ., wm] denote the class labels of m samples, where wi = k indicates the sample i being cancer k, where k = 1, . . ., K. Assume x1, . . ., xn are n genes. Let xij be the measurement of the expression level of the jth gene for the ith sample, where j = 1,2, . . ., n, X = [xij]m,n, denotes the expression levels of all genes, that is,

X=[Gene1Gene2Genenx11x12x1nx12x22x2nxm1xm2xmm].(1)

In the two proposed methods, every sample is partitioned by a series of optimal hyperplanes. The optimal hyperplane means training data is maximally distant from the hyperplane itself, and the lowest classification error rate will be achieved when using this hyperplane to classify current training set. These hyperplanes can be modeled as

ωstXiT+bst=0(2)

and the classification functions are defined as fst(XiT)=ωstXiT+bst, where Xi denotes the ith row of matrix X; s and t mean two partitions which are separated by an optimal hyperplane, and what these partitions mean lies on the construction of multiclass classification algorithms; for example, if we use binary classification tree, s and t mean two halves separated in an internal node, which may be the root node or a common internal node; if we use FSVM, s and t mean two arbitrary classes in K classes. ωst is an n-dimensional weight vector; bst is a bias term.

SVM algorithm is used to determinate these optimal hyperplanes. SVM is a learning algorithm originally introduced by Vapnik [17, 18] and successively extended by many other researchers. SVMs can work in combination with the technique of “kernels” that automatically do a nonlinear mapping to a feature space so that SVM can settle the nonlinear separation problems. In SVM, a convex quadratic programming problem is solved and, finally, optimal solutions of ωst and bst are given. Detailed solution procedures are found in [17, 18].

Along with each binary classification using SVM, one operation of gene selection is done in advance. Specific gene selection methods used in our paper are described briefly in “experimental results.” Here, gene selection is done before SVM trained means that when an SVM is trained or used for prediction, dimensionality reduction will be done on input data, Xi, referred to as the strongest genes selected. We use function Yi=I(βstXiT) to represent this procedure, where βst is an n × n matrix, in which only diagonal elements may be equal to 1 or 0; and all other elements are equal to 0; genes corresponding to the nonzero diagonal elements are important. βst is gotten by specific gene selection methods; function I() means to select all nonzero elements in the input vector to construct a new vector , for example, I([1 0 2])T = [1 2T]. So (2) is rewritten as

βstXiT+bst=0,Yi=I(βstXiT)(3)

and the classification functions are rewritten as fst(XiT)=βstXiT+bst accordingly.

In order to accelerate calculation rate, preselecting genes before the training of multiclass classifiers is adopted. Based on all above, we propose two different constructed multiclass classifiers with gene selection: (1) binary classification tree based on SVM with gene selection, and (2) FSVM with gene selection.

BINARY CLASSIFICATION TREE BASED ON SVM WITH GENE SELECTION

Binary classification tree is an important class of machine-learning algorithms for multiclass classification. We construct binary classification tree with SVM; for short, we call it BCT-SVM. In BCT-SVM, there are K − 1 internal nodes and K terminal nodes. When building the tree, the solution of (3) is searched by SVM at each internal node to separate the data in the current node into the left children node and right children node with appointed gene selection method, which is mentioned in “experimental results”. Which class or classes should be partitioned into the left (or right) children node is decided at each internal node by impurity reduction [19], which is used to find the optimal construction of the classifier. The partition scheme with largest impurity reduction (IR) is optimal. Here, we use Gini index as our IR measurement criterion, which is also used in classification and regression trees (CARTs) [20] as a measurement of class diversity. Denote as M the training dataset at the current node, as ML and MR the training datasets at the left and right children nodes, as Mi sample set of class i in the training set, as MR.i and ML.i sample sets of class i of the training dataset at the left and right children nodes; and we use λΘ to denote the number of samples in dataset Θ; the current IR can be calculated as follows, in which c means the number of classes in the current node:

IR(M)=1λMλMLi=1c(λMLi)2+1λMλMRi=1c(λMRi)21λM2i=1c(λMi)2.(4)

When the maximum of IR(M) is found out based on all potential combinations of classes in the current internal node, which part of data should be partitioned into the left children node is decided. For the details to construct the standard binary decision tree, we refer to [19, 20].

After this problem is solved, samples partitioned into the left children node are labeled with −1, and the others are labeled with 1, based on these measures, a binary SVM classifier with gene selection is trained using the data of the two current children nodes. As to gene selection, it is necessary because the cancer classification is a typical problem with small sample and large variables, and it will cause overfitting if we directly train the classifier with all genes; here, all gene selection methods based on two-class classfication could be used to construct βst in (3). The process of building a whole tree is recursive, as seen in Figure 1.

Figure 1.

Figure 1

Binary classification tree based on SVM with gene selection.

When the training data at a node cannot be split any further, that node is identified as a terminal node and what we get from decision function corresponds to the label for a particular class. Once the tree is built, we could predict the results of the samples with genes selected by this tree; trained SVM will bring them to a terminal node, which has its own label. In the process of building BCT-SVM, there are K − 1 operations of gene selection done. This is due to the construction of BCT-SVM, in which there are K − 1 SVMs.

FSVM WITH GENE SELECTION

Other than BCT-SVM, FSVM has a pairwise construction, which means every hyperplane between two arbitrary classes should be searched using SVM with gene selection. These processes are modeled by (3).

FSVM is a new method firstly proposed by Abe and Inoue in [21, 22]. It was proposed to deal with unclassifiable regions when using one versus the rest or pairwise classification method based on binary SVM for n(> 2)-class problems. FSVM is an improved pairwise classification method with SVM; a fuzzy membership function is introduced into the decision function based on pairwise classification. For the data in the classifiable regions, FSVM gives out the same classification results as pairwise classification with SVM method and for the data in the unclassifiable regions, FSVM generates better classification results than the pairwise classification with SVM method. In the process of being trained, FSVM is the same as the pairwise classification method with SVM that is referred to in [23].

In order to describe our proposed algorithm clearly, we denote four input variables: the sample matrix X0 = {x1 ,x2, . . ., xk, . . ., xm}T, that is, X0 is a matrix composed of some columns of original training dataset X, which corresponds to preselected important genes; the class-label vector y = {y1, y2, . . ., yk, . . ., ym}T; the number of classes in training set ν; and the number of important genes used in gene selection κ. With these four input variables, the training process of FSVM with gene selection is expressed in (Algorithm 1).

Algorithm 1.

Algorithm 1

The FSVM with gene selection training algorithm.

In Algorithm 1, υ = GeneSelection (μ, ϕ, κ) is realization of a specific binary gene selection algorithm, υ denotes the genes important for two specific draw-out classes and is used to construct βst in (3), SV MTrain() is realization of binary SVM algorithm, α is a Lagrange multiplier vector, and ϵ is a bias term. γ, alpha, and bias are the output matrixes. γ is made up of all important genes selected, in which each row corresponds to a list of important genes selected between two specific classes. alpha is a matrix with each row corresponding to Lagrange multiplier vector by an SVM classifier trained between two specific classes, and bias is the vector made up of bias terms of these SVM classifiers.

In this process, we may see there are K(K − 1)/2 SVMs trained and K(K − 1)/2 gene selections executed. This means that many important genes relative to two specific classes of samples will be selected.

Based on the K(K − 1)/2 optimal hyperplanes and the strongest genes selected, decision function is constructed based on (3). Define fst(Xi) = −fts(Xi), (st); the fuzzy membership function mst(Xi) is introduced on the directions orthogonal to fst(Xi) = 0 as

mst(Xi)={1forfst(Xi)1,fst(Xi)otherwise.(5)

Using mst(Xi)(st, s = 1, . . ., n), the class i membership function of Xi is defined as ms(Xi) = mint=1, . . ., nmst(Xi), which is equivalent to ms(Xi) = min(1, mins≠t,t=1, . . ., n fst(Xi)); now an unknown sample Xi is classified by argmaxs=1, . . ., nms(Xi).

EXPERIMENTAL RESULTS

F test and SVM-RFE are gene selection methods used in our experiments. In F test, the ratio R(j)=i=1m(k=1K1Ωi=k)(x¯kjx¯j)2/i=1m(k=1K1Ωi=k)(xijx¯kj)2,1jn, is used to select genes, in which x¯j denotes the average expression level of gene j across all samples and x¯kj denotes the average expression level of gene j across the samples belonging to class k where class k corresponds to {Ωi = k}; and the indicator function 1Ω is equal to one if event Ω is true and zero otherwise. Genes with bigger R(j) are selected. From the expression of R(j) , it can be seen F test could select genes among l(>3) classes [14]. As to SVM-RFE, it is recursive feature elimination based on SVM. It is a circulation procedure for eliminating features combined with training an SVM classifier and, for each elimination operation, it consists of three steps: (1) train the SVM classifier, (2) compute the ranking criteria for all features, and (3) remove the feature with the smallest ranking scores, in which all ranking criteria are relative to the decision function of SVM. As a linear kernel SVM is used as a classifier between two specific classes s and t, the square of every element of weight vector ωst in (2) is used as a score to evaluate the contribution of the corresponding genes. The genes with the smallest scores are eliminated. Details are referred to in [6]. To speed up the calculation, gene preselection is generally used. On every dataset we use the first important 200 genes are selected by F test before multiclass classifiers with gene selection are trained. Note that F test requires normality of the data to be efficient which is not always the case for gene expression data. That is the exact reason why we cannot only use F test to select genes. Since the P values of important genes are relatively low, that means the F test scores of important genes should be relatively high. Considering that the number of important genes is often among tens of genes, we preselect the number of genes as 200 according to our experience in order to avoid losing some important genes. In the next experiments, we will show this procedure works effectively.

Combining these two specific gene selection methods with the multiclass classification methods, we propose three algorithms: (1) BCT-SVM with F test, (2) BCT-SVM with SVM-RFE, and (3) FSVM with SVM-RFE. As mentioned in [4, 9], every algorithm is tested with cross-validation (leave-one-out) method based on top 5, top 10, and top 20 genes selected by their own gene selection methods.

Breast cancer dataset

In our first experiment, we will focus on hereditary breast cancer data, which can be downloaded from the web page for the original paper [24]. In [24], cDNA microarrays are used in conjunction with classification algorithms to show the feasibility of using differences in global gene expression profiles to separate BRCA1 and BRCA2 mutation-positive breast cancers. Twenty-two breast tumor samples from 21 patients were examined: 7 BRCA1, 8 BRCA2, and 7 sporadic. There are 3226 genes for each tumor sample. We use our methods to classify BRCA1, BRCA2, and sporadic. The ratio data is truncated from below at 0.1 and above at 20.

Table 1 lists the top 20 strongest genes selected by using our methods. (For reading purpose, sometimes instead of clone ID, we use the gene index number in the database [24].) The clone ID and the gene description of a typical column of the top 20 genes selected by SVM-RFE are listed in Table 2; more information about all selected genes corresponding to the list in Table 1 could be found at http://www.sensornet.cn/fxia/top_20_genes.zip. It is seen that gene 1008 (keratin 8) is selected by all the three methods. This gene is also an important gene listed in [4, 7, 9]. Keratin 8 is a member of the cytokeratin family of genes. Cytokeratins are frequently used to identify breast cancer metastases by immunohistochemistry [24]. Gene 10 (phosphofructokinase, platelet) and gene 336 (transducer of ERBB2, 1) are also important genes listed in [7]. Gene 336 is selected by FSVM with SVM-RFE and BCT-SVM with SVM-RFE; gene 10 is selected by FSVM with SVM-RFE.

Table 1.

The index no of the strongest genes selected in hereditary breast cancer dataset.

No FSVM with SVM-RFE BCT-SVM with F test BCT-SVM with SVM-RFE

1 2 3 1 2 1 2

1 1008 1859 422 501 1148 750 1999
2 955 1008 2886 2984 838 860 3009
3 1479 10 343 3104 1859 1008 158
4 2870 336 501 422 272 422 2761
5 538 158 92 2977 1008 2804 247
6 336 1999 3004 2578 1179 1836 1859
7 3154 247 1709 3010 1065 3004 1148
8 2259 1446 750 2804 2423 420 838
9 739 739 2299 335 1999 1709 1628
10 2893 1200 341 2456 2699 3065 1068
11 816 2886 1836 1116 1277 2977 819
12 2804 2761 219 268 1068 585 1797
13 1503 1658 156 750 963 1475 336
14 585 560 2867 2294 158 3217 2893
15 1620 838 3104 156 609 501 2219
16 1815 2300 1412 2299 1417 146 585
17 3065 538 3217 2715 1190 343 1008
18 3155 498 2977 2753 2219 1417 2886
19 1288 809 1612 2979 560 2299 36
20 2342 1092 2804 2428 247 2294 1446

Table 2.

A part of the strongest genes selected in hereditary breast cancer dataset (the first row of genes in Table 1).

Rank Index no Clone ID Gene description

1 1008 897781 Keratin 8
2 955 950682 Phosphofructokinase, platelet
3 1479 841641 Cyclin D1 (PRAD1: parathyroid adenomatosis 1)
4 2870 82991 Phosphodiesterase I/nucleotide pyrophosphatase 1
(homologous to mouse Ly-41 antigen)
5 538 563598 Human GABA-A receptor π subunit mRNA, complete cds
6 336 823940 Transducer of ERBB2, 1
7 3154 135118 GATA-binding protein 3
8 2259 814270 Polymyositis/scleroderma autoantigen 1 (75kd)
9 739 214068 GATA-binding protein 3
10 2893 32790 mutS (E coli) homolog 2 (colon cancer, nonpolyposis type 1)
11 816 123926 Cathepsin K (pycnodysostosis)
12 2804 51209 Protein phosphatase 1, catalytic subunit, beta isoform
13 1503 838568 Cytochrome c oxidase subunit VIc
14 585 293104 Phytanoyl-CoA hydroxylase (Refsum disease)
15 1620 137638 ESTs
16 1815 141959 Homo sapiens mRNA; cDNA DKFZp566J2446
(from clone DKFZp566J2446)
17 3065 199381 ESTs
18 3155 136769 TATA box binding protein (TBP)-associated factor,
RNA polymerase II, A, 250kd
19 1288 564803 Forkhead (drosophila)-like 16
20 2342 284592 Platelet-derived growth factor receptor, alpha polypeptide

Using the top 5, 10, and 20 genes each for these three methods, the recognition accuracy is shown in Table 3. When using top 5 genes for classification, there is one error for BCT-SVM with F test and no error for the other two methods. When using top 10 and 20 genes, there is no error for all the three methods. Note that the performance of our methods is similar to that in [4], where the authors diagnosed the tumor types by using multinomial probit regression model with Bayesian gene selection. Using top 10 genes, they also got zero misclassification.

Table 3.

Classifiers' performance on hereditary breast cancer dataset by cross-validation (number of wrong classified samples in leave-one-out test).

Classification method Top 5 Top 10 Top 20

FSVM with SVM-RFE 0 0 0
BCT-SVM with F test 1 0 0
BCT-SVM with SVM-RFE 0 0 0

Small round blue-cell tumors

In this experiment, we consider the small round blue-cell tumors (SRBCTs) of childhood, which include neuroblastoma (NB), rhabdomyosarcoma (RMS), nonHodgkin lymphoma (NHL), and the Ewing sarcoma (EWS) in [25]. The dataset of the four cancers is composed of 2308 genes and 63 samples, where the NB has 12 samples; the RMS has 23 samples; the NHL has 8 samples, and the EMS has 20 samples. We use our methods to classify the four cancers. The ratio data is truncated from below at 0.01.

Table 4 lists the top 20 strongest genes selected by using our methods. The clone ID and the gene description of a typical column of the top 20 genes selected by SVM-RFE are listed in Table 5; more information about all selected genes corresponding to the list in Table 4 could be found at http://www.sensornet.cn/fxia/top_20_genes.zip. It is seen that gene 244 (clone ID 377461), gene 2050 (clone ID 295985), and gene 1389 (clone ID 770394) are selected by all the three methods, and these genes are also important genes listed in [25]. Gene 255 (clone ID 325182), gene 107 (clone ID 365826), and gene 1 (clone ID 21652, (catenin alpha 1)) selected by BCT-SVM with SVM-RFE and FSVM with SVM-RFE are also listed in [25] as important genes.

Table 4.

The index no of the strongest genes selected in small round blue-cell tumors dataset.

No FSVM with SVM-RFE BCT-SVM with F test SVM-RFE SVM-RFE

1 2 3 4 5 6 1 2 3 1 2 3

1 246 255 1954 851 187 1601 1074 169 422 545 174 851
2 1389 867 1708 846 509 842 246 1055 1099 1389 1353 846
3 851 246 1955 1915 2162 1955 1708 338 758 2050 842 1915
4 1750 1389 509 1601 107 255 1389 422 1387 1319 1884 1601
5 107 842 2050 742 758 2046 1954 1738 761 1613 1003 742
6 2198 2050 545 1916 2046 1764 607 1353 123 1003 707 1916
7 2050 365 1389 2144 2198 509 1613 800 84 246 1955 2144
8 2162 742 2046 2198 2022 603 1645 714 1888 867 2046 2198
9 607 107 348 1427 1606 707 1319 758 951 1954 255 1427
10 1980 976 129 1 169 174 566 910 1606 1645 169 1
11 567 1319 566 1066 1 1353 368 2047 1914 1110 819 1066
12 2022 1991 246 867 1915 169 1327 2162 1634 368 509 867
13 1626 819 1207 788 788 1003 244 2227 867 129 166 788
14 1916 251 1003 153 1886 742 545 2049 783 348 1207 153
15 544 236 368 1980 554 2203 1888 1884 2168 365 603 1980
16 1645 1954 1105 2199 1353 107 2050 1955 1601 107 796 2199
17 1427 1708 1158 783 338 719 430 1207 335 1708 1764 783
18 1708 1084 1645 1434 846 166 365 326 1084 187 719 1434
19 2303 566 1319 799 1884 1884 1772 796 836 1626 107 799
20 256 1110 1799 1886 2235 1980 1298 230 849 1772 2203 1886

Table 5.

A part of the strongest genes selected in small round blue-cell tumors dataset (the first row of genes in Table 4).

Rank Index no Clone ID Gene description

1 246 377461 Caveolin 1, caveolae protein, 22kd
2 1389 770394 Fc fragment of IgG, receptor, transporter, alpha
3 851 563673 Antiquitin 1
4 1750 233721 Insulin-like growth factor binding protein 2 (36kd)
5 107 365826 Growth arrest-specific 1
6 2198 212542 H sapiens mRNA; cDNA DKFZp586J2118
(from clone DKFZp586J2118)
7 2050 295985 ESTs
8 2162 308163 ESTs
9 607 811108 Thyroid hormone receptor interactor 6
10 1980 841641 Cyclin D1 (PRAD1: parathyroid adenomatosis 1)
11 567 768370 tissue inhibitor of metalloproteinase 3
(Sorsby fundus dystrophy, pseudoinflammatory)
12 2022 204545 ESTs
13 1626 811000 Lectin, galactoside-binding, soluble, 3 binding
protein (galectin 6 binding protein)
14 1916 80109 Major histocompatibility complex, class II, DQ alpha 1
15 544 1416782 Creatine kinase, brain
16 1645 52076 Olfactomedinrelated ER localized protein
17 1427 504791 Glutathione S-transferase A4
18 1708 43733 Glycogenin 2
19 2303 782503 H sapiens clone 23716 mRNA sequence
20 256 154472 Fibroblast growth factor receptor 1
(fms-related tyrosine kinase 2, Pfeiffer syndrome)

Using the top 5, 10, and 20 genes for these three methods each, the recognition accuracy is shown in Table 6. When using top 5 genes for classification, there is one error for BCT-SVM with F test and no error for the other two methods. When using top 10 and 20 genes, there is no error for all the three methods.

Table 6.

Classifiers' performance on small round blue-cell tumors dataset by cross-validation (number of wrong classified samples in leave-one-out test).

Classification method Top 5 Top 10 Top 20

FSVM with SVM-RFE 0 0 0
BCT-SVM with F test 1 0 0
BCT-SVM with SVM-RFE 0 0 0

In [26], Yeo et al applied k nearest neighbor (kNN), weighted voting, and linear SVM in one-versus-rest fashion to this four-class problem and compared the performances of these methods when they are combined with several feature selection methods for each binary classification problem. Using top 5 genes, top 10 genes, or top 20 genes, kNN, weighted voting, or SVM combined with all the three feature selection methods, respectively, without rejection all have errors greater than or equal to 2. In [27], Lee et al used multicategory SVM with gene selection. Using top 20 genes, their recognition accuracy is also zero misclassification number.

Acute leukemia data

We have also applied the proposed methods to the leukemia data of [14], which is available at http://www.sensornet.cn/fxia/top_20_genes.zip. The microarray data contains 7129 human genes, sampled from 72 cases of cancer, of which 38 are of type B cell ALL, 9 are of type T cell ALL, and 25 of type AML. The data is preprocessed as recommended in [2]: gene values are truncated from below at 100 and from above at 16 000; genes having the ratio of the maximum over the minimum less than 5 or the difference between the maximum and the minimum less than 500 are excluded; and finally the base-10 logarithm is applied to the 3571 remaining genes. Here we study the 38 samples in training set, which is composed of 19 B-cell ALL, 8 T-cell ALL, and 11 AML.

Table 7 lists the top 20 strongest genes selected by using our methods. The clone ID and the gene description of a typical column of the top 20 genes selected by SVM-RFE are listed in Table 8; more information about all selected genes corresponding to the list in Table 7 could be found at http://www.sensornet.cn/fxia/top_20_genes.zip. It is seen that gene 1882 (CST3 cystatin C (amyloid angiopathy and cerebral hemorrhage)), gene 4847 (zyxin), and gene 4342 (TCF7 transcription factor 7 (T cell specific)) are selected by all the three methods. In the three genes, the first two are the most important genes listed in many literatures. Gene 2288 (DF D component of complement (adipsin)) is another important gene having biological significance, which is selected by FSVM with SVM-RFE.

Table 7.

The index no of the strongest genes selected in acute leukemia dataset.

No FSVM with SVM-RFE BCT-SVM with F test BCT-SVM with SVM-RFE

1 2 3 1 2 1 2

1 6696 1882 6606 2335 4342 1882 4342
2 6606 4680 6696 4680 4050 6696 4050
3 4342 6201 4680 2642 1207 5552 5808
4 1694 2288 4342 1882 6510 6378 1106
5 1046 6200 6789 6225 4052 3847 3969
6 1779 760 4318 4318 4055 5300 1046
7 6200 2335 1893 5300 1106 2642 6606
8 6180 758 1694 5554 1268 2402 6696
9 6510 2642 4379 5688 4847 3332 2833
10 1893 2402 2215 758 5543 1685 1268
11 4050 6218 3332 4913 1046 4177 4847
12 4379 6376 3969 4082 2833 6606 6510
13 1268 6308 6510 6573 4357 3969 2215
14 4375 1779 2335 6974 4375 6308 1834
15 4847 6185 6168 6497 6041 760 4535
16 6789 4082 2010 1078 6236 2335 1817
17 2288 6378 1106 2995 6696 2010 4375
18 1106 4847 5300 5442 1630 6573 5039
19 2833 5300 4082 2215 6180 4586 4379
20 6539 1685 1046 4177 4107 2215 5300

Table 8.

A part of the strongest genes selected in small round blue-cell tumors dataset (the second row of genes in Table 4).

Rank Index no Gene accession number Gene description

1 1882 M27891_at CST3 cystatin C (amyloid angiopathy and cerebral hemorrhage)
2 4680 X82240_rna1_at TCL1 gene (T-cell leukemia) extracted from H sapiens
mRNA for T-cell leukemia/lymphoma 1
3 6201 Y00787_s_at Interleukin-8 precursor
4 2288 M84526_at DF D component of complement (adipsin)
5 6200 M28130_rna1_s_at Interleukin-8 (IL-8) gene
6 760 D88422_at Cystatin A
7 2335 M89957_at IGB immunoglobulin-associated beta (B29)
8 758 D88270_at GB DEF = (lambda) DNA for immunoglobin light chain
9 2642 U05259_rna1_at MEF2C MADS box transcription enhancer factor 2,
polypeptide C (myocyte enhancer factor 2C)
10 2402 M96326_rna1_at Azurocidin gene
11 6218 M27783_s_at ELA2 Elastatse 2, neutrophil
12 6376 M83652_s_at PFC properdin P factor, complement
13 6308 M57731_s_at GRO2 GRO2 oncogene
14 1779 M19507_at MPO myeloperoxidase
15 6185 X64072_s_at SELL leukocyte adhesion protein beta subunit
16 4082 X05908_at ANX1 annexin I (lipocortin I)
17 6378 M83667_rna1_s_at NF-IL6-beta protein mRNA
18 4847 X95735_at Zyxin
19 5300 L08895_at MEF2C MADS box transcription enhancer factor 2,
polypeptide C (myocyte enhancer factor 2C)
20 1685 M11722_at Terminal transferase mRNA

Using the top 5, 10, and 20 genes for these three methods each, the recognition accuracy is shown in Table 9. When using top 5 genes for classification, there is one error for FSVM with SVM-RFE, two errors for BCT-SVM with SVM-RFE and BCT-SVM with F test, respectively. When using top 10 genes for classification, there is no error for FSVM with SVM-RFE, two errors for BCT-SVM with SVM-RFE and four errors for BCT-SVM with F test. When using top 20 genes for classification, there is one error for FSVM with SVM-RFE, two errors for BCT-SVM with SVM-RFE and two errors for BCT-SVM with F test. Again note that the performance of our methods is similar to that in [4], where the authors diagnosed the tumor types by using multinomial probit regression model with Bayesian gene selection. Using top 10 genes, they also got zero misclassification.

Table 9.

Classifiers' performance on acute leukemia dataset by cross-validation (number of wrong classified samples in leave-one-out test).

Classification method Top 5 Top 10 Top 20

FSVM with SVM-RFE 1 0 1
BCT-SVM with F test 2 4 2
BCT-SVM with SVM-RFE 2 1 2

ANALYSIS AND DISCUSSION

According to Tables 19, there are many important genes selected by these three multiclass classification algorithms with gene selection. Based on these selected genes, the prediction error rate of these three algorithms is low.

By comparing the results of these three algorithms, we consider that FSVM with SVM-RFE algorithm generates the best results. BCT-SVM with SVM-RFE and BCT-SVM with F test have the same multiclass classification structure. The results of BCT-SVM with SVM-RFE are better than those of BCT-SVM with F test, because their gene selection methods are different; a better gene selection method combined with the same multiclass classification method will perform better. It means SVM-RFE is better than F test combined with multiclass classification methods; the results are similar to what is mentioned in [6], in which the two gene selection methods are combined with two-class classification methods.

FSVM with SVM-RFE and BCT-SVM with SVM-RFE have the same gene selection methods. The results of FSVM with SVM-RFE are better than those of BCT-SVM with SVM-RFE whether in gene selection or in recognition accuracy, because the constructions of their multiclass classification methods are different, which is explained in two aspects. (1) The genes selected by FSVM with SVM-RFE are more than those of BCT-SVM with SVM-REF. In FSVM there are K(K − 1)/2 operations of gene selection, but in BCT-SVM there are only K −1 operations of gene selection. An operation of gene selection between every two classes is done in FSVM with SVM-RFE; (2) FSVM is an improved pairwise classification method, in which the unclassifiable regions being in BCT-SVM are classified by FSVM's fuzzy membership function [21, 22]. So, FSVM with SVM-RFE is considered as the best of the three.

CONCLUSION

In this paper, we have studied the problem of multiclass cancer classification with gene selection from gene expression data. We proposed two different new constructed classifiers with gene selection, which are FSVM with gene selection and BCT-SVM with gene selection. F test and SVM-RFE are used as our gene selection methods combined with multiclass classification methods. In our experiments, three algorithms (FSVM with SVM-RFE, BCT-SVM with SVM-RFE, and BCT-SVM with F test) are tested on three datasets (the real breast cancer data, the small round blue-cell tumors, and the acute leukemia data). The results of these three groups of experiments show that more important genes are selected by FSVM with SVM-RFE, and by these genes selected it shows higher prediction accuracy than the other two algorithms. Compared to some existing multiclass cancer classifiers with gene selection, FSVM based on SVM-RFE also performs very well. Finally, an explanation is provided on the experimental results of this study.

ACKNOWLEDGMENT

This work is supported by China 973 Program under Grant no 2002CB312200 and Center of Bioinformatics Program grant of Harvard Center of Neurodegeneration and Repair, Harvard University, Boston, USA.

References

  • 1.Zhou X, Wang X, Pal R, Ivanov I, Bittner M, Dougherty E.R. A Bayesian connectivity-based approach to constructing probabilistic gene regulatory networks. Bioinformatics. 2004;20(17):2918–2927. doi: 10.1093/bioinformatics/bth318. [DOI] [PubMed] [Google Scholar]
  • 2.Dudoit S, Fridlyand J, Speed T.P. Comparison of discrimination methods for the classification of tumors using gene expression data. Journal of the American Statistical Association. 2002;97(457):77–87. [Google Scholar]
  • 3.Nguyen D.V, Rocke D.M. Multi-class cancer classification via partial least squares with gene expression profiles. Bioinformatics. 2002;18(9):1216–1226. doi: 10.1093/bioinformatics/18.9.1216. [DOI] [PubMed] [Google Scholar]
  • 4.Zhou X, Wang X, Dougherty E.R. Multi-class cancer classification using multinomial probit regression with Bayesian variable selection. IEE Proc of System Biology. doi: 10.1049/ip-syb:20050015. In press. [DOI] [PubMed] [Google Scholar]
  • 5.Zhang H.P, Yu C.Y, Singer B, Xiong M. Recursive partitioning for tumor classification with gene expression microarray data. Proc Natl Acad Sci USA. 2001;98(12):6730–6735. doi: 10.1073/pnas.111153698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Machine Learning. 2002;46(1–3):389–422. [Google Scholar]
  • 7.Kim S, Dougherty E.R, Barrera J, Chen Y, Bittner M.L, Trent J.M. Strong feature sets from small samples. J Comput Biol. 2002;9(1):127–146. doi: 10.1089/10665270252833226. [DOI] [PubMed] [Google Scholar]
  • 8.Zhou X, Wang X, Dougherty E.R. Nonlinear-probit gene classification using mutual-information and wavelet based feature selection. Biological Systems. 2004;12(3):371–386. [Google Scholar]
  • 9.Lee K.E, Sha N, Dougherty E.R, Vannucci M, Mallick B.K. Gene selection: a Bayesian variable selection approach. Bioinformatics. 2003;19(1):90–97. doi: 10.1093/bioinformatics/19.1.90. [DOI] [PubMed] [Google Scholar]
  • 10.Zhou X, Wang X, Dougherty E.R. Gene selection using logistic regression based on AIC, BIC and MDL criteria. New Mathematics and Natural Computation. 2005;1(1):129–145. [Google Scholar]
  • 11.Zhou X, Wang X, Dougherty E.R. A Bayesian approach to nonlinear probit gene selection and classification. Franklin Institute. 2004;341(1-2):137–156. [Google Scholar]
  • 12.Zhou X, Wang X, Dougherty E.R. Missing-value estimation using linear and non-linear regression with Bayesian gene selection. Bioinformatics. 2003;19(17):2302–2307. doi: 10.1093/bioinformatics/btg323. [DOI] [PubMed] [Google Scholar]
  • 13.Jornsten R, Yu B. Simultaneous gene clustering and subset selection for sample classification via MDL. Bioinformatics. 2003;19(9):1100–1109. doi: 10.1093/bioinformatics/btg039. [DOI] [PubMed] [Google Scholar]
  • 14.Golub T.R, Slonim D.K, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531–537. doi: 10.1126/science.286.5439.531. [DOI] [PubMed] [Google Scholar]
  • 15.Furey T.S, Cristianini N, Duffy N, Bednarski D.W, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics. 2000;16(10):906–914. doi: 10.1093/bioinformatics/16.10.906. [DOI] [PubMed] [Google Scholar]
  • 16.Mukherjee S, Tamayo P, Mesirov J.P, Slonim D, Verri A, Poggio T. CBCL Paper 182/AI Memo 1676. Cambridge, Mass: Massachusetts Institute of Technology; 1999. Support Vector Machine Classification of Microarray Data. [Google Scholar]
  • 17.Vapnik V.N. Statistical Learning Theory. New York, NY: John Wiley & Sons; 1998. [Google Scholar]
  • 18.Vapnik V.N. The Nature of Statistical Learning Theory. 2nd ed. New York, NY: Springer; 2000. [Google Scholar]
  • 19.Duda R.O, Hart P.E, Stork D.G. Pattern Classification. 2nd ed. New York, NY: John Wiley & Sons; 2001. [Google Scholar]
  • 20.Breiman L, Friedman J.H, Olshen R.A, Stone C.J. Classification and Regression Trees. Belmont, Calif: Wadsworth; 1984. [Google Scholar]
  • 21.Abe S, Inoue T, editors. Fuzzy support vector machines for multiclass problems. In: European Symposium on Artificial Neural Networks Bruges; Belgium. 2002. pp. 113–118. [Google Scholar]
  • 22.Inoue T, Abe S, editors. Fuzzy support vector machines for pattern classification. In: Proceeding of International Joint Conference on Neural Networks; Washington DC. 2001. pp. 1449–1454. [Google Scholar]
  • 23.Kreßel U.H-G. Pairwise classification and support vector machines. In: Schölkopf B, Burges C.J.C, Smola A.J, editors. Advances in Kernel Methods—Support Vector Learning. Cambridge, Mass: MIT Press; 1999. pp. 255–268. [Google Scholar]
  • 24.Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344(8):539–548. doi: 10.1056/NEJM200102223440801. [DOI] [PubMed] [Google Scholar]
  • 25.Khan J, Wei J.S, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001;7(6):673–679. doi: 10.1038/89044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yeo G, Poggio T. CBLC Paper 206/AI Memo 2001-018. Cambridge, Mass: Massachusetts Institute of Technology; 2001. Multiclass Classification of SRBCTs. [Google Scholar]
  • 27.Lee Y, Lin Y, Wahba G. Multicategory support vector machines: theory and application to the classification of microarray data and satellite radiance data. American Statistical Association. 2004;99(465):67–81. [Google Scholar]

Articles from Journal of Biomedicine and Biotechnology are provided here courtesy of Wiley

RESOURCES